Tandem Diabetes Care(US:TNDM) ZACKS·2025-08-06 22:51分组1 - Tandem Diabetes Care reported a quarterly loss of $0.48 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.4, and compared to a loss of $0.47 per share a year ago, indicating a surprise of -20.00% [1] - The company posted revenues of $240.68 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.87%, and showing an increase from year-ago revenues of $221.91 million [2] - The stock has underperformed significantly, losing about 57.9% since the beginning of the year, while the S&P 500 gained 7.1% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$0.26 on revenues of $253.39 million, and for the current fiscal year, it is -$1.36 on revenues of $1.01 billion [7] - The Zacks Industry Rank for Medical - Instruments is currently in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8] - The estimate revisions trend for Tandem Diabetes Care was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6]